Shanghai No.1 PharmacyLtd Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Jun Yao

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	1.3yrs
CEO ownership	n/a
Management average tenure	no data
Board average tenure	4.4yrs

Recent management updates

Recent updates

Shanghai No.1 PharmacyLtd's (SHSE:600833) Shareholders Have More To Worry About Than Only Soft Earnings

Apr 09

CEO

Jun Yao (50 yo)

1.3yrs

Tenure

Board Members

Name	Position	Tenure	Compensation	Ownership
Haibo Zhang	Deputy GM	3.1yrs	CN¥1.15m	no data
Ping Wu	Director	5.3yrs	no data	no data
Xiaolong Shi	Director	7.7yrs	no data	no data
Junpei Cheng	Independent Director	5.8yrs	CN¥74.00k	no data
Wei Sun	Chairman	2.4yrs	no data	no data
Jin Biao Li	Director	5.3yrs	no data	no data
Li Feng	Chairman of the Board of Supervisors	3.5yrs	no data	no data
Songlian Tang	Independent Director	1.8yrs	CN¥40.00k	no data

4.4yrs

Average Tenure

50yo

Average Age

Experienced Board: 600833's board of directors are considered experienced (4.4 years average tenure).

Shanghai No.1 PharmacyLtd Management

Management criteria checks 1/4

Key information

Recent management updates

Shanghai No.1 Pharmacy Co.,Ltd., Annual General Meeting, Apr 29, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Shanghai No.1 PharmacyLtd's (SHSE:600833) Shareholders Have More To Worry About Than Only Soft Earnings

Shanghai No.1 Pharmacy Co.,Ltd., Annual General Meeting, Apr 29, 2024

Full year 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.64 in FY 2022)

Shanghai No.1 Pharmacy Co.,Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Investor sentiment deteriorates as stock falls 16%

Shanghai No.1 Pharmacy Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

Second quarter 2023 earnings released: EPS: CN¥0.072 (vs CN¥0.12 in 2Q 2022)

Investor sentiment deteriorates as stock falls 15%

Investor sentiment improves as stock rises 16%

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.045 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.071 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS: CN¥0.028 (vs CN¥0.045 in 1Q 2021)

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS: CN¥0.22 (vs CN¥0.31 in FY 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.045 (vs CN¥0.11 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.071 (vs CN¥0.066 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.045 (vs CN¥0.084 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.31 (vs CN¥0.24 in FY 2019)

New 90-day low: CN¥9.15

New 90-day low: CN¥9.35

New 90-day low: CN¥10.41

Third quarter earnings released

New 90-day low: CN¥10.55

First half earnings released

Shanghai No.1 Pharmacy Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

CEO

Tenure

Board Members

Average Tenure

Average Age